Researchers sought to determine whether rivaroxaban may be superior to low-molecular-weight heparin for reducing all-cause mortality.
Researchers are examining the role of platelets as drivers of inflammation, which may provide a mechanistic link with ischemia-reperfusion injury.
This the first study to evaluate the risk for venous thromboembolism by lupus nephritis class, according to investigators.
Investigators examined the effects of antithrombotic drugs on fecal immunochemical tests (FITs) for detection of colorectal neoplasms (CN).
Researchers sought to determine whether decitabine could improve platelet counts and survival rates in patients with RPIT.
Researchers attempted to develop a predictive model for the risk of postpartum hemorrhage in patients who have ITP.
Researchers sought to improve outcomes for pregnant patients with cTTP using prophylactic FFP.
Researchers sought to determine whether patients with ITP treated with eltrombopag would have SROT.
The American Society of Hematology released guidelines for preventing and managing venous thromboembolism in patients with cancer.
Hemoglobin levels, platelet counts, creatinine levels, and ADAMTS13 activity were all significantly higher in the general TMA group.
Researchers attempted to revise clinically relevant definitions for patients with iTTP in light of recent changes.
Researchers sought to assess the incidence of thrombotic complications in the second wave of patients with COVID-19, how many patients had diagnostic imaging for these complications, overall mortality, and then compared these outcomes with the first wave.
A team of researchers conducted a meta-analysis to determine the variation in incidence of venous thromboembolism following resection for colorectal cancer.
Results of a rodent model show that fibrin-specific core-shell nanogels with a tissue-type plasminogen activator warrants more study as a treatment for patients with DIC.
Immigrants may be at a lower risk for mortality after ischemic stroke compared with long-term residents, but the risk for vascular event recurrence was similar in both populations.
A team of investigators conducted an observational study to evaluate the incidence of venous thromboembolism and whether early anticoagulation affected survival in critically ill patients with COVID-19.
A novel assay for evaluating ADAMTS13 activity may be both fast and reliable for the diagnosis of thrombotic thrombocytopenic purpura (TTP), according to the results of a study published in Research and Practice in Thrombosis and Hemostasis. A thrombotic microangiopathy that can be life-threatening, TTP can be diagnosed only through measurement of ADAMTS13 activity, which…
Risk for stroke or systemic embolism not increased with low-to-moderate drinking; no increased risk found for bleeding
A single-institution chart review of patients with TTP showed evidence that they may be at higher risk for VTE; therefore, there may be a need to implement VTE thromboprophylaxis earlier for hospitalized patients.
A letter to the editor drew attention to the increased risk of thrombotic disorder for patients with severe COVID-19, which seems to occur by interacting with the von Willebrand Factor-ADAMTS13 axis.
A team of researchers sought to determine the frequency of and risk factors associated with ischemic stroke in patients with immune thrombotic thrombocytopenic purpura.
Researchers identified predictive markers — including plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA — for the pathogenesis of and prognosis for patients with iTTP.
The FDA has issued guidance to facilitate the availability of coagulation systems during the COVID-19 pandemic.
A population-based analysis suggested that plasma levels of von Willebrand factor may be a potential biomarker for the future risk of incident venous thromboembolism.
A recently published review outlines the approach to the treatment of venous thromboembolism in pregnancy using patient case studies from their clinical practice in a Netherlands-based academic hospital.
Among pediatric patients with cerebral venous thrombosis, treatment with rivaroxaban or standard anticoagulants resulted in a similarly reduced risk for recurrent VTE or bleeding.
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Although mycophenolate is often used as second-line treatment for immune thrombocytopenia, its efficacy as first-line treatment in combination with corticosteroids is unknown.
Researchers from the Medical University of Vienna highlight diagnostic and management strategies for the treatment of cyclic thrombocytopenia.
Researchers evaluated coagulation-linked complications in critically ill patients with COVID-19 and survival outcomes following therapeutic anticoagulation.
A 2-fold increase in mortality was seen among patients with thrombotic thrombocytopenic purpura compared with the general US population.
Study results confirmed that dabigatran has comparable efficacy and safety as standard of care heparin or vitamin K antagonists for acute VTE in children.
With close monitoring, the discontinuation of eculizumab is safe in the majority of patients with atypical hemolytic uremic syndrome.
A novel diagnostic algorithm was able to safely rule out DVT in patients visiting an emergency department, thereby reducing the need for ultrasound imaging.
A team of investigators examined the effect of a history of venous thromboembolism on recurrence of thrombosis in patients with cancer.
A retrospective analysis showed similar outcomes for cyclophosphamide as seen with rituximab in treatment of immune thrombotic thrombocytopenic purpura.
A retrospective analysis shows that real-world outcomes with caplacizumab for thrombotic thrombocytopenic purpura are similar to clinical trial results.
In minor procedures, coagulation differences may not be clinically significant to determine bleeding or thrombotic periprocedure complication risks.
Patients with thrombophilia demonstrate an elevated risk for venous thromboembolism after undergoing orthopedic surgery.
Caplacizumab with therapeutic plasma exchange and immunosuppression appears to prevent unfavorable clinical outcomes in patients with immune-mediated TTP.
Survey results suggest significant alignment among patients and physicians about symptom burden of ITP, but not frequency or severity of fatigue.
The risk for venous thromboembolism is steadily increasing among patients with cancer compared with the general population.
Prothrombotic autoantibodies, similar to those with antiphospholipid syndrome, appear to be elevated in hospitalized patients with COVID-19.
A pair of researchers discuss the treatment and specific clinical challenges associated with thrombotic thrombocytopenic purpura in women who are pregnant.
In a new study, researchers reported on the frequency of VTE among more than 6000 patients who tested positive for infection with SARS-CoV-2.
Hospitalized patients with elevated Sdc-1 levels have a higher risk for death in patients with iTTP. Levels may be used for risk stratification.
New research has not found RBC transfusion to be an independent risk factor for venous or arterial thrombosis in hospitalized patients.
Investigators compared first-line dexamethasone with prednisone on admission and readmission rates among patients with acute immune thrombocytopenia.
A single-center study in Canada found a point prevalence of Gaucher disease of 0.5% among Canadian patients referred to a hematologist for thrombocytopenia.
There might be notable variations among hematology, oncology, and bone marrow transplant practitioners when treating thrombotic events in children with leukemia.
A team of researchers evaluated the current health system-wide practices and protocols associated with the administration of DOACs in anticoagulation clinics.